0.04
0.00%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HeraMED
Its shares trade on ASX under the ticker HMD.AX. It has been listed since 12 December 2018. In the fiscal year to 31 December 2024, it reported revenue of A$364,300 and a net loss of A$5.5m. At that date it held total assets of A$4.5m and shareholders' equity of A$2.8m.
HeraMED Ltd. engages in the development and production of pregnancy monitoring solutions for home and professional use. The company offers hardware solutions supported by software applications. Its product HeraBEAT, is a medical-grade, clinically-validated and connected Ultrasound Fetal Doppler device predominantly for use by an expectant mother to self-monitor her fetus’ heart rate (FHR) at home. HeraBEAT communicates with any smartphone (iOS/Android) through Bluetooth Low Energy (BLE). A mother can hold or strap the HeraBEAT device to her abdomen, and the collected data is transmitted to her smartphone where the relevant readings are displayed through an interface. The firm also develops a service model which includes a homecare pregnancy solution. In addition, the Company develops artificial intelligence (AI), machine-learning, computerized algorithms to monitor and analyze the data so a healthcare professional or home user is informed of the wellbeing of the fetus.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 12 Dec 2018
- Website
- hera-med.com ↗
Leadership
Pay as last reported
- Mr. Tim ChapmanChairman of the Board, since 2024
- Ms. Anoushka GungadinChief Executive Officer, Managing Director, Director, since 2022
- Mr. Cameron JonesChief Financial Officer, Company Secretary
- Mrs. Sivan SadanExecutive Vice President - Business DevelopmentA$175,654
- Mr. David HintonNon-Executive DirectorA$30,044
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HeraBEAT is a medical-grade, clinically-validated connected ultrasound fetal doppler device for home use.
- HeraMED Ltd. develops AI and machine-learning algorithms for fetal monitoring and analysis.
- HeraMED Ltd. offers a homecare pregnancy solution with hardware and software support.
Weaknesses
- HeraMED Ltd. is listed on the Tel Aviv Stock Exchange since 12 December 2018.
- HeraMED Ltd. operates from Netanya, Israel, which may limit market access.
- HeraMED Ltd. focuses solely on pregnancy monitoring solutions without diversification.
Opportunities
- Expanding into the global health care market for home pregnancy monitoring solutions.
- Increasing demand for AI-driven health monitoring tools in the health care sector.
- Growing adoption of Bluetooth Low Energy technology in medical devices.
Threats
- Competition from established medical device manufacturers in the health care industry.
- Regulatory changes affecting medical device approvals in Israel and international markets.
- Economic downturns impacting consumer spending on non-essential health products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.